Biogen Weighs Aduhelm Lessons Ahead Of Lecanemab Launch
Plans for launching a second Alzheimer's drug, lecanemab, will be scaled back compared to Aduhelm, the firm predicted, though partner Eisai has not finalized Biogen's commercial role yet.
You may also be interested in...
Biogen will likely add sales reps to support Eisai’s US commercial launch of the Alzheimer’s drug early next year when treatment capacity increases.
Any given year sees a variety of clinical trials produce positive or negative results. But some of those trials are especially important either for moving a field forward or for a company’s overall development and commercial strategy. Here, Scrip looks at some of the more notable trial successes of the last year.
Christopher Viehbacher, former Sanofi CEO and current managing partner at Gurnet Capital, will be charged with returning Biogen to growth with a second big Alzheimer’s launch looming.